Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18995860 | 0.86 | CYP2D6 (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL15570938 | 0.86 | CA12 (0.49) | CA12CA1CA2CA9CA14 | |
| SCHEMBL16096641 | 0.83 | ALDH1A1 (0.38) | CA12CA1CA2CA9CA14 | |
| SCHEMBL14682168 | 0.81 | ALDH1A1 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1605930 | 0.79 | ERN1 (0.49) | CA12CA1CA2CA9LMNA | |
| SCHEMBL30937481 | 0.79 | ERN1 (0.49) | CA12CA1CA2CA9LMNA | |
| SCHEMBL9586812 | 0.77 | CCNB2 (0.53) | LMNAALDH1A1SMN1; SMN2HPGDHTT | |
| SCHEMBL3819637 | 0.77 | CA12 (0.58) | CA12CA1CA2CA9CA14 | |
| Formic Acid SCHEMBL28135766 | 0.76 | CA12 (0.54) | CA12CA1CA2CA9CA14 | |
| SCHEMBL15065468 | 0.76 | HTR1A (0.50) | LMNAALDH1A1HTTSLC6A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11434234-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. | 2021-10-21 | — | — | US | disclosed |
| CN-107531631-B | Methods and agents for treating diseases | 安吉昂生物医药公司 | 2021-09-03 | — | — | CN | disclosed |
| US-10851095-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10287282-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3240778-A1 | METHODS AND AGENTS FOR TREATING DISEASE | Angion Biomedica Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109492-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | CA12 1565/4885CA1 3956/4885CA2 1386/4885 |
| US-11434234-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | CA12 1379/4885CA1 3671/4885CA2 1150/4885 |
| US-10851095-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | CA12 1379/4885CA1 3671/4885CA2 1150/4885 |
| US-10287282-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | CA12 1565/4885CA1 3956/4885CA2 1386/4885 |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | CA12 1379/4885CA1 3671/4885CA2 1150/4885 |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | CA12 1379/4885CA1 3671/4885CA2 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.